Comparing the current results to its competitors, Pasithea Therapeutics reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 290.13 %, recorded in the same quarter.
Pasithea Therapeutics 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancements and a focus on proprietary product candidates. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions can concentrate resources among fewer competitors. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Smaller or early-stage companies may be significant competitors, particularly through collaborations with larger firms. Additionally, potential competitors may hold patents or rights that conflict with the company's technologies.
September 16, 2025
: Pasithea Therapeutics Corp. (Nasdaq: KTTA) has recently made significant strides in its clinical research initiatives by activating clinical trial sites in South Korea for its Phase 1/1b study of PAS-004, aimed at treating adult patients with Neurofibromatosis Type 1 (NF1). This development marks an important step in addressing the needs of patients suffering from this chronic condition. However, the company faces financial challenges as evidenced by a stagnant year-on-year revenue in the second quarter of 2025, contrasting sharply with the substantial growth observed among its competitors.Neurofibromatosis Type 1 (NF1) is a genetic disorder characterized by the development of tumors along nerves in the sk...
September 26, 2024
Pasithea Therapeutics has released initial results from its Phase 1 clinical trial for PAS-004, a novel therapeutic candidate aimed at treating advanced cancers, particularly those associated with neurofibromatosis type 1 (NF1) and MAPK pathway alterations. The findings indicate promising safety, tolerability, and preliminary efficacy outcomes, marking a significant step in the development of targeted cancer therapies. The development of effective treatments for advanced cancers remains a critical area of research, particularly for malignancies driven by genetic mutations or pathway dysregulation, such as neurofibromatosis type 1 (NF1) and MAPK-driven cancers. Pasithea Therapeutics has initiated clinical...
September 9, 2024
In the rapidly evolving world of biotech, where breakthroughs can happen overnight but financial challenges loom ominously, Pasithea Therapeutics finds itself at a pivotal crossroads. Recently, the company announced the successful completion of its chronic toxicity studies for PAS-004, a promising investigational treatment aimed at addressing the complex needs of patients with Neurofibromatosis Type 1 (NF1) and cancer. However, with these scientific strides comes the harsh reality of a significant financial downturn a stark juxtaposition of innovation and fiscal vulnerability.The results from the chronic toxicity studies for PAS-004 have painted a hopeful picture for the future of long-term treatment optio...
April 24, 2024
Pasithea Therapeutics (Nasdaq: KTTA) recently reached a significant milestone in their groundbreaking PAS-004 Phase 1 trial. This trial aims to evaluate the safety and efficacy of PAS-004 in patients with RAS, NF1, and RAF mutated cancers. The completion of initial dosing marks a major step forward in the development of precision treatments for these challenging and complex cancer types. With safety data expected in the second half of 2024, Pasithea Therapeutics is demonstrating its commitment to improving the lives of cancer patients worldwide.Pasithea Therapeutics: Revolutionizing Cancer Treatment:Pasithea Therapeutics is a pioneering biotechnology company known for its dedication to identifying novel ther...
Publicly Traded Peers of Pasithea Therapeutics Corp
Alzamend Neuro Inc Share Performance
-28.22%
One Year
Alzamend Neuro Inc
Profile
Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer's disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.
Clearmind Medicine Inc operates as a healthcare company that provides innovative mental health solutions, leveraging advanced technology and research-backed treatments. Their business model focuses on developing and delivering personalized mental health therapies, utilizing a combination of telehealth services, virtual reality technology, and data-driven treatment plans.
Compass Pathways Plc is a mental healthcare company focused on developing innovative therapies for treatment-resistant depression. They are pioneering the use of psychedelic-assisted therapy to address this significant unmet medical need. With a business model centered around clinical research and drug development, their goal is to bring their therapies to market and improve the lives of patients suffering from depression.
Sources:
Pasithea Therapeutics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pasithea Therapeutics Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
